StockNews.com Upgrades AC Immune (NASDAQ:ACIU) to “Buy”

AC Immune (NASDAQ:ACIU) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday.

Separately, HC Wainwright dropped their price target on AC Immune from $16.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, May 1st.

AC Immune Stock Performance

Shares of NASDAQ:ACIU opened at $1.53 on Tuesday. AC Immune has a 52-week low of $1.43 and a 52-week high of $4.98. The company has a 50-day simple moving average of $1.78 and a 200 day simple moving average of $2.49. The company has a market capitalization of $153.63 million, a P/E ratio of -3.33 and a beta of 1.62.

AC Immune (NASDAQ:ACIU) last announced its earnings results on Wednesday, April 30th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.01. The firm had revenue of $1.12 million for the quarter, compared to the consensus estimate of $1.99 million. As a group, equities analysts forecast that AC Immune will post -0.62 earnings per share for the current year.

Hedge Funds Weigh In On AC Immune

Several institutional investors and hedge funds have recently added to or reduced their stakes in ACIU. Quinn Opportunity Partners LLC acquired a new position in AC Immune in the 4th quarter valued at approximately $27,000. Two Sigma Advisers LP bought a new stake in shares of AC Immune during the 4th quarter valued at about $36,000. Boothbay Fund Management LLC acquired a new stake in shares of AC Immune during the 4th quarter worth approximately $38,000. Banque Cantonale Vaudoise bought a new stake in AC Immune in the 1st quarter valued at about $50,000. Finally, RPO LLC acquired a new stake in AC Immune in the 4th quarter valued at $51,000. Institutional investors own 51.36% of the company’s stock.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.